Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry.
Asta TheodorsdottirBirgit DebrabantMelinda MagyariMatthias KantPeter V RasmussenCarl-Fredrik MalmbergIver A NorbergVictoria HansenDanny BechMathias F SchmidtKaren SchreiberJette L FrederiksenFinn SellebjergZsolt IllesPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)
In a country with primarily escalation strategy, relapse rate reduction was maintained for 5 years, and EDSS stabilized/improved in majority of patients. Higher relapse rate 1 year before alemtuzumab increased the odds for additional courses. Novel serious AEs were not observed.